, Volume 10, Issue 4, pp 355–358 | Cite as

Ashkenazi Parkinson’s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries

  • Anat Bar-Shira
  • Carolyn M. Hutter
  • Nir Giladi
  • Cyrus P. Zabetian
  • Avi Orr-UrtregerEmail author
Short Communication


The LRRK2 G2019S mutation is a major genetic determinant of Parkinson’s disease (PD) across the world that occurs at an elevated frequency in Ashkenazi Jews. We determined the LRRK2 haplotypes in 77 G2019S carriers, mostly Ashkenazi Jews, and in 50 noncarrier Ashkenazi PD patients, using 16 genetic markers. A single haplotype was detected in all mutation carriers, indicating that these individuals share a common founder. Using a maximum-likelihood method, we estimate that Ashkenazi Jews with G2019S share a common ancestor who lived ∼1,830 (95% CI 1,560–2,160) years ago, around the second century, after the second Jewish Diaspora.


Parkinson’s disease Haplotype Ashkenazi Jews LRRK2 G2019S mutation Founder mutation 



The assistance of Dr. Helena Yagev-More is gratefully acknowledged. This work was supported by grants from National Parkinson Foundation, Miami, USA, Tel Aviv Sourasky Medical Center Grant of Excellence, and Wolfson and Kahn Foundations.


The experiments were complied with the current laws of Israel, the country in which they were performed.

Supplementary material

10048_2009_186_MOESM1_ESM.xls (44 kb)
Supplementary Table. LRRK2 G2019S Haplotypes (XLS 43 KB)


  1. 1.
    de Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S21–S23PubMedGoogle Scholar
  2. 2.
    Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62:353–357. doi: 10.1001/archneur.62.3.353 CrossRefPubMedGoogle Scholar
  3. 3.
    Hernandez DG, Paisan-Ruiz C, McInerney-Leo A et al (2005) Clinical and positron emission tomography of Parkinson’s disease caused by LRRK2. Ann Neurol 57:453–456. doi: 10.1002/ana.20401 CrossRefPubMedGoogle Scholar
  4. 4.
    Healy DG, Falchi M, O’Sullivan SS et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 7:583–590. doi: 10.1016/S1474-4422(08)70117-0 CrossRefPubMedGoogle Scholar
  5. 5.
    Lesage S, Durr A, Tazir M et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 354:422–423. doi: 10.1056/NEJMc055540 CrossRefPubMedGoogle Scholar
  6. 6.
    Ozelius LJ, Senthil G, Saunders-Pullman R et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 354:424–425. doi: 10.1056/NEJMc055509 CrossRefPubMedGoogle Scholar
  7. 7.
    Orr-Urtreger A, Shifrin C, Rozovski U et al (2007) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 69:1595–1602. doi: 10.1212/01.wnl.0000277637.33328.d8 CrossRefPubMedGoogle Scholar
  8. 8.
    Goldwurm S, Di Fonzo A, Simons EJ et al (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor. J Med Genet 42:e65. doi: 10.1136/jmg.2005.035568 CrossRefPubMedGoogle Scholar
  9. 9.
    Kachergus J, Mata IF, Hulihan M et al (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672–680. doi: 10.1086/429256 CrossRefPubMedGoogle Scholar
  10. 10.
    Lesage S, Leutenegger AL, Ibanez P et al (2005) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330–332. doi: 10.1086/432422 CrossRefPubMedGoogle Scholar
  11. 11.
    Warren L, Gibson R, Ishihara L et al (2008) A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson’s disease. Parkinsonism Relat Disord 14:77–80. doi: 10.1016/j.parkreldis.2007.02.001 CrossRefPubMedGoogle Scholar
  12. 12.
    Zabetian CP, Hutter CM, Yearout D et al (2006) LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752–758. doi: 10.1086/508025 CrossRefPubMedGoogle Scholar
  13. 13.
    Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76:449–462. doi: 10.1086/428594 CrossRefPubMedGoogle Scholar
  14. 14.
    Genin E, Tullio-Pelet A, Begeot F et al (2004) Estimating the age of rare disease mutations: the example of Triple-A syndrome. J Med Genet 41:445–449. doi: 10.1136/jmg.2003.017962 CrossRefPubMedGoogle Scholar
  15. 15.
    Fenner JN (2005) Cross-cultural estimation of the human generation interval for use in genetics-based population divergence studies. Am J Phys Anthropol 128:415–423. doi: 10.1002/ajpa.20188 CrossRefPubMedGoogle Scholar
  16. 16.
    Tremblay M, Vezina H (2000) New estimates of intergenerational time intervals for the calculation of age and origins of mutations. Am J Hum Genet 66:651–658. doi: 10.1086/302770 CrossRefPubMedGoogle Scholar
  17. 17.
    Struewing JP, Abeliovich D, Peretz T et al (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200. doi: 10.1038/ng1095-198 CrossRefPubMedGoogle Scholar
  18. 18.
    Bar-Sade RB, Theodor L, Gak E et al (1997) Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? Eur J Hum Genet 5:413–416PubMedGoogle Scholar
  19. 19.
    Bar-Sade RB, Kruglikova A, Modan B et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet 7:801–805. doi: 10.1093/hmg/7.5.801 CrossRefPubMedGoogle Scholar
  20. 20.
    Goodman RM MAe, (1979) Genetic diseases among Ashkenazi Jews. New York: Raven PressGoogle Scholar
  21. 21.
    Hulihan MM, Ishihara-Paul L, Kachergus J et al (2008) LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 7:591–594. doi: 10.1016/S1474-4422(08)70116-9 CrossRefPubMedGoogle Scholar
  22. 22.
    Bras J, Guerreiro R, Ribeiro M et al (2008) Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. BMC Neurol 8:1. doi: 10.1186/1471-2377-8-1 CrossRefPubMedGoogle Scholar
  23. 23.
    Ferreira JJ, Guedes LC, Rosa MM et al (2007) High prevalence of LRRK2 mutations in familial and sporadic Parkinson’s disease in Portugal. Mov Disord 22:1194–1201. doi: 10.1002/mds.21525 CrossRefPubMedGoogle Scholar
  24. 24.
    Bras JM, Guerreiro RJ, Ribeiro MH et al (2005) G2019S dardarin substitution is a common cause of Parkinson’s disease in a Portuguese cohort. Mov Disord 20:1653–1655. doi: 10.1002/mds.20682 CrossRefPubMedGoogle Scholar
  25. 25.
    Benamer HT (2008) The ancestry of LRRK2 Gly2019Ser parkinsonism. Lancet Neurol 7:769–770. doi: 10.1016/S1474-4422(08)70178-9 author reply 770-771CrossRefPubMedGoogle Scholar
  26. 26.
    Zabetian CP, Morino H, Ujike H et al (2006) Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 67:697–699. doi: 10.1212/01.wnl.0000227732.37801.d4 CrossRefPubMedGoogle Scholar
  27. 27.
    Ross OA, Spanaki C, Griffith A et al (2008) Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord . doi: 10.1016/j.parkreldis.2008.09.001 Google Scholar
  28. 28.
    Haugarvoll K, Rademakers R, Kachergus JM et al (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:1456–1460. doi: 10.1212/01.wnl.0000304044.22253.03 CrossRefPubMedGoogle Scholar
  29. 29.
    Mata IF, Cosentino C, Marca V et al (2008) LRRK2 mutations in patients with Parkinson’s disease from Peru and Uruguay. Parkinsonism Relat Disord . doi: 10.1016/j.parkreldis.2008.09.002 PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Anat Bar-Shira
    • 1
  • Carolyn M. Hutter
    • 4
  • Nir Giladi
    • 2
    • 3
  • Cyrus P. Zabetian
    • 5
    • 6
  • Avi Orr-Urtreger
    • 1
    • 3
    Email author
  1. 1.Genetic InstituteTel Aviv Sourasky Medical CenterTel AvivIsrael
  2. 2.Movement Disorders Unit Parkinson Center, Department of NeurologyTel-Aviv Sourasky Medical CenterTel AvivIsrael
  3. 3.The Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael
  4. 4.Department of Epidemiology, School of Public Health and Community MedicineUniversity of WashingtonSeattleUSA
  5. 5.Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care SystemUniversity of Washington School of MedicineSeattleUSA
  6. 6.Department of NeurologyUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations